Page last updated: 2024-12-07

(tetrazol-5-yl)glycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

(Tetrazol-5-yl)glycine, also known as **5-amino-1H-tetrazole-1-acetic acid**, is a heterocyclic compound with a tetrazole ring and a glycine side chain. Its structural formula is:

**[Image of (Tetrazol-5-yl)glycine structure]**

This compound is important in research because:

* **Analog of Glycine:** It's a structural analog of glycine, an important amino acid involved in various biological processes. This similarity allows it to be used as a probe for glycine receptors and other glycine-binding sites.
* **Potential Therapeutic Agent:** (Tetrazol-5-yl)glycine has shown potential as a therapeutic agent in various areas, including:
* **Anti-inflammatory:** Studies have shown it possesses anti-inflammatory properties.
* **Neuroprotection:** It might offer neuroprotective effects against neuronal damage.
* **Anti-cancer:** It's being explored for its potential anti-cancer activity.
* **Chemical Reactivity:** Its tetrazole ring exhibits unique chemical reactivity, making it useful in organic synthesis.

However, it's essential to note that research on (Tetrazol-5-yl)glycine is still ongoing, and its exact mechanisms of action and potential therapeutic applications are yet to be fully elucidated. More studies are needed to understand its safety and efficacy for therapeutic use.

**Here are some additional details about (Tetrazol-5-yl)glycine:**

* **Synthesis:** It can be synthesized using various chemical methods.
* **Solubility:** It's soluble in water and other polar solvents.
* **Stability:** It's relatively stable under normal conditions.

Overall, (Tetrazol-5-yl)glycine holds significant potential for research due to its structural resemblance to glycine, its potential therapeutic applications, and its unique chemical properties.

(tetrazol-5-yl)glycine: potent NMDA receptor agonist; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID126383
CHEMBL ID140784
CHEBI ID35003
SCHEMBL ID10231795
MeSH IDM0199035

Synonyms (52)

Synonym
HMS3266G07
BPBIO1_001214
BIOMOL-NT_000191
tet-glycine
138199-51-6
5-tetrazolyl-glycine
NCGC00024531-02
CHEMBL140784
chebi:35003 ,
2-amino-2-(2h-tetrazol-5-yl)acetic acid
AKOS006272482
(tetrazol-5-yl)glycine
unii-u9ysj8vxx9
u9ysj8vxx9 ,
tetrazol-5-yl-gly
ly 285 265
1h-tetrazole-5-acetic acid, alpha-amino-, (+-)-
ly-285,265
tetrazolylglycine
(rs)-(tetrazol-5-yl)glycine
gtpl4068
2-amino-2-(1h-1,2,3,4-tetrazol-5-yl)acetic acid
AKOS024048687
2-amino-2-(2h-1,2,3,4-tetrazol-5-yl)acetic acid
SCHEMBL10231795
sr-01000597632
SR-01000597632-1
AS-62518
J-007105
A11450
2-amino-2-(1h-tetrazol-5-yl)acetic acid
Z1198152530
HMS3675E07
HY-100839
d,l-(tetrazol-5-yl)glycine;ly 285265
HMS3411E07
Q7706775
(rs)-2-(tetrazol-5-yl)glycine
alpha-tetrazolylglycine
2h-tetrazole-5-acetic acid, alpha-amino-
CS-0020483
T-205
2-amino-2-(2h-tetrazol-5-yl)acetic acid.
DTXSID70897242
.alpha.-amino-2h-tetrazole-5-acetic acid
ly-285265
ly285265
2h-tetrazole-5-acetic acid, .alpha.-amino-
1h-tetrazole-5-acetic acid, .alpha.-amino-
1h-tetrazole-5-acetic acid, .alpha.-amino-, (+/-)-
EN300-173114
2-amino-2-(2h-tetrazol-5-yl)aceticacid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Dose-response showed that DL-(tetrazol-5-yl)glycine was about 100 and 500 times more potent than cis-methanoglutamate and NMDA, respectively."( The NMDA receptor agonist DL-(tetrazol-5-yl)glycine is a highly potent excitotoxin.
Lunn, WH; McDonald, JW; Salhoff, CR; Schoepp, DD, 1994
)
0.87
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
non-proteinogenic alpha-amino acidAny alpha-amino acid which is not a member of the group of 23 proteinogenic amino acids.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (9)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency10.00000.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency79.43285.623417.292931.6228AID485281
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.600310.0000AID144612
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.630610.0000AID144612
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)IC50 (µMol)0.09800.00061.525710.0000AID144612
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.747210.0000AID144612
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.741110.0000AID144612
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.741110.0000AID144612
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)IC50 (µMol)0.09800.00071.741110.0000AID144612
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Glutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)EC50 (µMol)1.05000.00301.29038.3000AID144321; AID144322
Glutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)EC50 (µMol)1.05000.00301.02226.8600AID144321; AID144322
Glutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)EC50 (µMol)1.05000.00300.86696.8600AID144321; AID144322
Glutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)EC50 (µMol)1.05000.00301.11276.8600AID144321; AID144322
Glutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)EC50 (µMol)1.05000.00301.39378.3000AID144321; AID144322
Glutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)EC50 (µMol)1.05000.00300.90516.8600AID144321; AID144322
Glutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)EC50 (µMol)1.05000.00300.90516.8600AID144321; AID144322
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (2)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 1 Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2A Rattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2CRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 2DRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3BRattus norvegicus (Norway rat)
endoplasmic reticulum membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
plasma membraneGlutamate receptor ionotropic, NMDA 3ARattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID144322Compound was evaluated for the inhibition of [3H]norepinephrine binding at N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy.
AID144321Compound was evaluated for the inhibition of [3H]MK-801 binding at N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy.
AID144612Compound was evaluated for the inhibition of [3H]-CGS-19,755 binding at N-methyl-D-aspartate glutamate receptor1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
DL-tetrazol-5-ylglycine, a highly potent NMDA agonist: its synthesis and NMDA receptor efficacy.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (13)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (61.54)18.2507
2000's4 (30.77)29.6817
2010's1 (7.69)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.48

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.48 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.19 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.48)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]